When viewing this topic in a different language, you may notice some differences in the way the content is structured, but it still reflects the latest evidence-based guidance.

Câncer colorretal

Última revisão: 30 Sep 2024
Última atualização: 09 Jul 2024

Resumo

Definição

História e exame físico

Principais fatores diagnósticos

  • presença de fatores de risco
  • idade mais avançada
  • sangramento retal
  • alteração no hábito intestinal
  • massa retal
  • história familiar positiva
  • massa abdominal
Detalhes completos

Outros fatores diagnósticos

  • anemia
  • sexo masculino
  • dor abdominal
  • perda de peso e anorexia
  • distensão abdominal
  • linfonodos palpáveis
Detalhes completos

Fatores de risco

  • idade mais avançada
  • história familiar
  • mutação de polipose adenomatosa do cólon
  • Síndrome de Lynch (câncer colorretal hereditário sem polipose)
  • Polipose associada ao MYH/MUTYH
  • síndromes da polipose hamartomatosa
  • doença inflamatória intestinal
  • obesidade
  • acromegalia
  • atividade física limitada
  • ausência de fibras alimentares
  • tabagismo
  • consumo moderado ou excessivo de bebidas alcoólicas
  • níveis baixos de vitamina D
  • consumo de carne vermelha e processada
Detalhes completos

Investigações diagnósticas

Primeiras investigações a serem solicitadas

  • hemograma completo
  • bioquímica hepática
  • função renal
  • teste imunoquímico fecal quantitativo
  • colonoscopia
  • colonografia por TC
  • enema de bário com duplo contraste
  • TC do tórax, abdome e pelve
  • teste genético
Detalhes completos

Investigações a serem consideradas

  • RNM de pelve: protocolo para câncer retal
  • ultrassonografia endoscópica transrretal
  • biópsia
  • antígeno carcinoembriogênico
  • tomografia por emissão de pósitrons (PET)
Detalhes completos

Novos exames

  • técnicas avançadas de imagem óptica

Algoritmo de tratamento

Aguda

câncer retal, adequado para cirurgia

câncer retal, não adequado para cirurgia

câncer de cólon, adequado para cirurgia

câncer de cólon, não adequado para cirurgia

Colaboradores

Autores

David E. Stein, MD, FACS, FASCRS

Professor of Surgery

Georgetown University School of Medicine

Georgetown

DC

Regional Chief of Surgery

MedStar Health

Baltimore

MD

Declarações

DES declares that he has no competing interests.

Pallavi P. Kumar, MD

Division Director, Medical Oncology

Sinai and Northwest Hospital

LifeBridge Health

Alvin & Lois Lapidus Cancer Institute

Baltimore

MD

Declarações

PPK declares that she has no competing interests.

Kamila A. Nowak-Choi, MD

Assistant Professor

Department of Radiation Oncology

University of Maryland Upper Chesapeake Medical Center KCC Radiation Oncology

Bel Air

MD

Declarações

KANC declares that she has no competing interests.

Agradecimentos

Dr David E. Stein, Dr Pallavi P. Kumar, and Dr Kamila A. Nowak-Choi would like to gratefully acknowledge Dr David M. Lisle, Dr Juan L. Poggio, Dr Jascha Rubin, Dr Najjia Mahmoud, Dr Emily Carter Paulson, Dr Gary Atkin, Dr Anne Ballinger, Dr Mark O'Hara, Dr Mark Harrison, and Dr Robert Glynne-Jones, previous contributors to this topic.

Declarações

DML, JLP, JR, NM, ECP, MOH, GA, and AB declare that they have no competing interests. MH is the chair of the Mount Vernon Upper GI Tumour Site Specific Group and a member of the National Cancer Research Institute anal, rectal, and advanced colorectal groups. He has also received honoraria for speaking and has been supported to attend international meetings on gastrointestinal cancer from Roche. He has also received research funding from Pfizer for a trial in rectal cancer. RGJ is the chief medical adviser to the charity Bowel Cancer UK. He has received honoraria for lectures from Roche, Sanofi, and Pfizer. He has received funding for the EXTRA study, involving capecitabine and radiotherapy in anal cancer, published in the International Journal of Radiation Biology Physics. RGJ has also received funding and free cetuximab for an ongoing phase 1/2 study integrating cetuximab into chemoradiation in rectal cancer, and has an agreement from Roche to supply bevacizumab for 3 months to 60 patients in one randomised phase 2 study as neoadjuvant chemotherapy in rectal cancer (BACCHUS). He has also been supported by Roche to attend international meetings in gastrointestinal cancer.

Revisores

Susan Clark, BChir, MB

Consultant Colorectal Surgeon

St Mark's Hospital and Academic Institute

Northwick Park

Middlesex

UK

Declarações

SC declares that she has no competing interests.

Steven Wexner, MD, FACS, FRCS, FRCS Ed, FASCRS, FAC

Chief of Staff

Chairman

Department of Colorectal Surgery

Cleveland Clinic

Weston

FL

Declarações

SW declares that he has no competing interests.

  • Diagnósticos diferenciais

    • Síndrome do intestino irritável
    • Colite ulcerativa
    • Doença de Crohn
    Mais Diagnósticos diferenciais
  • Diretrizes

    • NNCN clinical practice guidelines in oncology: colon cancer
    • NCCN clinical practice guidelines in oncology: management of immunotherapy-related toxicities
    Mais Diretrizes
  • Folhetos informativos para os pacientes

    Bowel cancer: should I be screened?

    Bowel cancer: what is it?

    Mais Folhetos informativos para os pacientes
  • padlock-lockedConectar-se ou assinar para acessar todo o BMJ Best Practice

O uso deste conteúdo está sujeito ao nosso aviso legal